Fig 2.

Meta-analysis of the prognostic impact of assigned B-cell–associated gene signature (BAGS) subtypes. (A, C, E) Overall survival and (B, D, F) progression-free survival were compared between BAGS subtypes for patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). For overall survival, the following three cohorts were used: Lymphoma/Leukemia Molecular Profiling Project (LLMPP) R-CHOP, International Diffuse Large B-Cell Lymphoma Rituximab-CHOP Consortium MD Anderson Project (IDRC), and Mayo Clinic, Brigham and Women's Hospital, and Dana-Farber Cancer Institute Project (MDFCI). For progression-free survival, only LLMPP R-CHOP and IDRC were used. The comparisons were performed (A, B) overall and according to the (C, D) activated B-cell–like and (E, F) germinal center B-cell–like subclasses based on Kaplan-Meier survival curves, log-rank test P values, and hazard ratios. For clarity, the naive and unclassified cells were excluded from the Kaplan-Meier analysis. CB, centroblast; CC, centrocyte; M, memory; PB, plasmablast.